BLA

<!-- Name:DistributionId Value:8740311 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

Saint-Herblain (France), December 23, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that it has completed rolling submission of the Biologics License Application (BLA) to the U.S.…

CT-P13 SC is a novel subcutaneous formulation of infliximab The Biologics License Application (BLA) submission is based on phase III pivotal data that evaluated the efficacy and safety of CT-P13 SC as maintenance therapy in patients…